Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093272 · ClinicalTrials.gov registry record · Phase 2
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03093272 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants.
The verdict
NCT03093272, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Docetaxel (a type of chemotherapy) * Apalutamide (the study medication, also known as ARN-509) * Prednisone (a corticosteroid given to prevent reactions to docetaxel). * Leuprolide acetate (also known as Lupron, a GnRH agonist or similar drug which is standard of care, causes chemical castration which greatly lowers the level of testosterone in the body)
Interventions
- DRUG Docetaxel
- DRUG Apalutamide
- DRUG Prednisone
- DRUG Leuprolide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-06-23 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03093272
The ClinicalTrials.gov registry entry for NCT03093272 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT03093272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03093272 about?
NCT03093272 is a clinical study titled "A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer". This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Docetaxel (a type of chemotherapy) * Apalutamide (the study medication, also known as ARN-509) * Prednisone (a corticosteroid giv...
What is the current status of trial NCT03093272?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-06-23. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03093272?
The interventions under investigation include: Docetaxel (DRUG), Apalutamide (DRUG), Prednisone (DRUG), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT03093272?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.